Bausch Health Companies Inc
Bausch Health Companies Inc (BHC) is a diversified healthcare company known for prescription and consumer products in eye care, dermatology, gastroenterology and branded generics. Operating across North America, Europe and emerging markets, the company’s performance depends on product sales, pipeline development and how it manages pricing and patent expiries. Investors should be aware that BHC has a relatively small market capitalisation (~$2.3bn) and has historically carried significant leverage alongside episodic litigation and regulatory scrutiny — factors that can increase volatility and affect cash flow. Key watch points include product launches, integration of acquisitions, margin trends and debt reduction progress. This summary is educational only and not personalised advice; values can rise or fall and past performance is not a guide to future returns. Consider your risk tolerance and consult a financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts advise holding Bausch Health stock, with a target price slightly above its current value.
Financial Health
Bausch Health is generating solid revenue and profits, with strong cash flow supporting its operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BHC
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: August 29, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Revenue & Brands
Established prescription and consumer brands drive sales, while new launches and patent expiries shape growth — though revenues can fluctuate with market and competitive pressures.
Balance Sheet Focus
Leverage and debt reduction are important for valuation; successful deleveraging could improve prospects, but indebtedness and legal costs remain material risks.
Global Footprint
A presence across developed and emerging markets offers diversification and growth potential, yet it also brings currency, regulatory and pricing challenges.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
